

## Report Information

More information from: <https://www.marketresearchfuture.com/reports/pharmaceutical-grade-lactose-market-4816>

# Pharmaceutical grade lactose Market Research Report - Global Forecast till 2032

Report / Search Code: MRFR/Pharma/3389-CR

Publish Date: February, 2021

Request Sample

Price	1-user PDF : \$ 4950.0	Site PDF : \$ 5950.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------	----------------------------

## Description:

## Global Pharmaceutical Grade Lactose Market Overview

The pharmaceutical grade lactose market size was valued at USD 0.2 Billion in 2022. The pharmaceutical grade lactose industry is projected to grow from USD 0.21 Billion in 2023 to USD 0.29 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.40% during the forecast period (2023 - 2032). The expansion in awareness about the advantages of consuming pharmaceutical grade lactose products and growing awareness regarding the importance of infant nutrition are the key market drivers enhancing the market growth.

### Pharmaceutical Grade Lactose Market

**Source: Secondary Research, Primary Research, MRFR Database and Analyst Review**

Increases in healthcare spending around the world are expected to boost economies everywhere. Several companies compete in the pharmaceutical grade lactose market, providing the market and its many different consumers. Gaining an edge over the competition requires more than just doing well in the market. Key market drivers boosting market growth include expanding awareness of the benefits of ingesting pharmaceutical grade lactose products and growing understanding of the importance of baby nutrition.

The rising demand for food and infant-grade lactose is the primary factor in the market's CAGR for pharmaceutical grade lactose. The demand for infant formula has increased dramatically, especially in the developed countries of the United States and Europe. One of the world's largest consumers of baby formula, China has long had to rely on imports to meet its needs. China's newfound preference for domestically produced goods has helped the country's major manufacturers.

In addition, the market for pharma grade lactose has been given a boost by the participation of a number of regional firms. Pharmaceutical grade lactose is highly sought after because of its excellent qualities for use in the production of oral medicines. The rise of the tablet market can be directly attributed to the widespread adoption of pharmaceutical-grade lactose in their production. The pharmaceutical business relies on high-quality lactose since it imparts notable curative effects.

Foreign and domestic investors' increasing interest in the pharmaceutical manufacturing sector in emerging markets like India and Brazil bodes well for the future of the sector. Additionally, the expansion of the drug manufacturing business has contributed to rising product demand because of increased accessibility to medication as a result of generic drug production and novel therapies for chronic diseases.

In July 2023, GSK of the United Kingdom established sustainable sourcing criteria for ingredients such as lactose, gelatin, palm oil, paper, and sugar to mitigate the negative effects of its operations on the environment and biodiversity. As part of the Science Based Targets Network's (SBTN) pilot of science-based targets for nature, major pharmaceutical firm GSK is assessing its supply chain and formulating a mitigation plan in light of these nature-based impacts. Only GSK, out of the total of 17, is a pharmaceutical business involved in the pilot.

## Pharmaceutical Grade Lactose Market Trends

- **Increasing demand for food and infant-grade lactose is driving market growth.**

Market CAGR for pharmaceutical grade lactose is driven by the increasing demand for food and infant-grade lactose. Infant formula has seen a significant increase in demand, particularly from industrialised nations like the US and major European nations. For a long time, China, one of the world's biggest users of baby formula, was reliant on imports. The largest domestic manufacturers in the nation have benefited from China's change in emphasis towards homegrown brands. Among the market leaders in China for baby formula are China Feihe and Inner Mongolia Yili Industrial Group Co. Due to the high demand for its infant formula brands in China during the 2019–2020 fiscal year, China Feihe saw a 38% rise in sales.

Additionally, pharma grade lactose has gathered traction from several regional players, which has given a thrust to the growth of the market. The popularity of the pharmaceutical grade lactose market owes to its splendid properties for manufacturing oral medications. The use of pharmaceutical grade lactose in the manufacture of tablets has played a vital role in the growth of the market. Grade lactose endows commendable healing properties, the primary reason behind its use in the pharmaceutical industry. Moreover, grad lactose is also present in milk, with a total content

percentage of around 8%. The utility of pharmaceutical grade lactose in multiple areas within healthcare shall aid market growth.

Growing investments by local and foreign players in the pharmaceutical manufacturing sector, particularly in developing economies such as India and Brazil, are anticipated to influence industry growth positively. Furthermore, improved access to medication through generic drug production and the development of creative treatments for chronic diseases has resulted in the development of the drug manufacturing industry, thereby driving product demand. According to the WHO and Centers for Disease Control and Prevention, 30% of the entire world population does not have access to lactose nutrients, and another 15% of the people are incompetent to digest lactose and utilize substitute variants for nutrition.

The rising need from the dairy industry will also aid in expanding the market for pharmaceutical grade lactose in the coming years. The plentiful accessibility of milk across numerous provincial pockets has assumed a fundamental part in the development of the worldwide pharmaceutical grade lactose market lately. Test meds' readiness also includes utilizing the pharmaceutical grade lactose market. Steady unofficial laws and low costs offered by item makers are expected to be the key variables impacting item interest in pharmaceutical applications in the coming years, driving the pharmaceutical grade lactose market revenue.

## Pharmaceutical grade lactose Market Segment Insights

### Pharmaceutical Grade Lactose Type Insights

The pharmaceutical grade lactose market segmentation, based on type, includes crystalline monohydrate lactose, inhalation lactose, granulated lactose, and spray dried lactose. The granulated lactose segment dominated the market, accounting for 35% of market revenue (0.07 Billion). In developing economies, category growth is driven by rising demand from infant formula and pharmaceutical industries for refined-edible grade lactose combined with innovative product offerings, such as dry-blend infant-grade lactose, by the market players. However, crystalline monohydrate lactose is the fastest-growing category over the forecast period due to the rising applications in feed manufacturing and fermentation applications driving the market growth over the forecast period.

### Pharmaceutical Grade Lactose Application Insights

The pharmaceutical grade lactose market segmentation, based on application, includes tablet manufacturing and capsule manufacturing. The capsule manufacturing category generated the most income (70.4%). Capsules are a widely known oral dosage formulation common among pharmaceutical companies and consumers. While buyers comprehend the tasteless and easy-to-take capsules, the pharmaceutical industry appreciates the streamlined development timelines and manufacturing simplicity. However, tablet manufacturing is the fastest-growing category due to the product's ease of absorption, cost-effectiveness, and disintegration driving the market growth.

Figure 1: Pharmaceutical Grade Lactose Market, by Application, 2022 & 2032 (USD Billion)

Pharmaceutical Grade Lactose Market, by Application, 2022 & 2032 (USD Billion)

**Source: Secondary Research, Primary Research, MRFR Database and Analyst Review**November 2022: Because of the significant maintenance costs associated with transporting and storing ethanol, Fonterra decided in November 2022 to transform their Trau milk processing plant into a high-value lactose production hub. The cooperative has spent \$40 million on concentrating whey permeate so that it may be more easily transported to its other locations where lactose is produced. The co-op sees a higher return on its investment in lactose production than in the production of ethanol, which was previously done at Tirau.

### Pharmaceutical Grade Lactose Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North America pharmaceutical grade lactose market will dominate this market, owing to the favorable business policies regarding the dairy sector and the higher demand for refined-edible grade lactose from the pharmaceutical industry. Further, the US pharmaceutical grade lactose market held the largest market share, and the Canada pharmaceutical grade lactose market was the fastest-growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: PHARMACEUTICAL GRADE LACTOSE MARKET SHARE BY REGION 2022 (USD Billion)

PHARMACEUTICAL GRADE LACTOSE MARKET SHARE BY REGION 2022 (USD Billion)

**Source: Secondary Research, Primary Research, MRFR Database and Analyst Review**

Europe pharmaceutical grade lactose market accounts for the second-largest market share due to the increased trend of outsourcing pharmaceutical products in the region, coupled with the existence of a well-established healthcare sector in this region. Further, the German pharmaceutical grade lactose market held the largest market share, and the UK pharmaceutical grade lactose market was the fastest-growing market in the European region.

The Asia-Pacific pharmaceutical grade lactose market is expected to grow at the fastest CAGR from 2023 to 2032. This is owing to the increasing birth rate in emerging economies, including China and India, leading to growth in product demand for infant formulations. Moreover, the China pharmaceutical grade lactose market held the largest market share, and the Indian pharmaceutical grade lactose market was the fastest-growing market in the Asia-Pacific region.

### Pharmaceutical Grade Lactose Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the pharmaceutical grade lactose market grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the pharmaceutical grade lactose industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the pharmaceutical grade lactose industry to benefit clients and increase the market sector. Major players in the pharmaceutical grade lactose market, including Kerry Inc. (Ireland), DFE Pharma (Germany), Meggle Excipients & Technology (Germany), Merck KGaA (Germany), Armor Pharma (France), and others, are attempting to increase market demand by investing in research and development operations.

Royal FrieslandCampina NV, a subsidiary of Zuivelcoöperatie FrieslandCampina UA, produces and sells dairy products. The company's product portfolio includes dairy-based beverages, condensed milk, cream, nutrition products, yogurt, butter, milk powders, cheese, desserts and functional ingredients. FrieslandCampina markets its products under Edam, Gouda, Maasdam, Dutch Lady, Frico and Milli brands. It provides dairy products to professional customers such as pastry chefs, bakers, chefs, caterers and chocolate confectioners and sells ingredients to manufacturers of infant nutrition, the pharmaceutical sector and the food industry worldwide. The company has a business presence across Europe, Asia and Oceania, North and South America, Africa and the Middle East. In September 2021, FrieslandCampina Ingredients relaunched its infant nutrition brand Friso in the Netherlands market to expand its brand presence there.

Molkerei MEGGLE Wasserburg GmbH & Co KG provides dairy products. The Company offers yogurt, butter, cream, and other related products. Molkerei MEGGLE Wasserburg operates in Germany. In April 2023, Pharmaceutical lactose specialist MEGGLE launched a platform for its latest inhalable lactose grade, InhaLac® 180. InhaLac® 180 is tailored to dry powder inhalation (DPI) applications with a highly uniform particle size distribution (PSD) of X10=5-15µm, X50=50-100µm, and X90=120-160µm and characterized by the typical flow and surface characteristics of milled lactose.

#### Key Companies in the pharmaceutical grade lactose market include

- General Mills Inc.
- Amway
- Conagra Brands Inc.
- Cargill Incorporated
- Abbott Laboratories
- Kraft Foods Group Inc.
- The Coca-Cola Company
- PepsiCo Inc.
- Atkins Nutritionals Inc.
- Brunswick Corporation

#### Pharmaceutical Grade Lactose Industry Developments

**July 2022:** DFE Pharma, a leader in pharma- and nutraceutical excipient solutions, announces the expansion of its dry powder inhalation (DPI) portfolio with the launch of Lactohale 400. Adding Lactohale 400 further enhances the completeness of DFE Pharma's portfolio of inhalation grade lactose.

**July 2022:** Danone launched the first ever Dairy and Plants Blend baby formula in response to parents' desire for vegetarian and flexitarian options for their babies. Plant-based consumption is growing substantially, with over one-third [37%] of EU consumers choosing a vegan, vegetarian or flexitarian diet, and almost 70% [69%] of parents now preferring their children to eat more plant-based foods. Until now, there have been rare options for parents if they choose to move on from breastmilk and want to create healthier, more plant-based food choices and good for the planet.

## Pharmaceutical grade lactose Market Segmentation

### Pharmaceutical Grade Lactose Type Outlook

- Crystalline Monohydrate Lactose

- Inhalation Lactose
- Granulated Lactose
- Spray Dried Lactose

## Pharmaceutical Grade Lactose Application Outlook

- Tablets Manufacturing
- Capsule Manufacturing

## Pharmaceutical Grade Lactose Regional Outlook

- North America
  - US
  - Canada
- Europe
  - Germany
  - France
  - UK
  - Italy
  - Spain
  - Rest of Europe
- Asia-Pacific
  - China
  - Japan
  - India

- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
  - Middle East
  - Africa
  - Latin America

**Table of Content:**

Contents	
1 EXECUTIVE SUMMARY	
1.1 OVERVIEW	16
1.1.1 MARKET SYNOPSIS	16
2 MARKET INTRODUCTION	
2.1 SCOPE OF THE STUDY	17
2.2 RESEARCH OBJECTIVE	17
2.3 LIST OF ASSUMPTIONS	17
3 RESEARCH METHODOLOGY	
3.1 OVERVIEW	19
3.2 DATA MINING	19
3.3 SECONDARY RESEARCH	19
3.4 PRIMARY RESEARCH	20
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS	21
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS	21
3.5 FORECASTING TECHNIQUES	22
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION	23
3.6.1 BOTTOM-UP APPROACH	23
3.6.2 TOP-DOWN APPROACH	24
3.7 DATA TRIANGULATION	24
3.8 VALIDATION	24
4 MARKET DYNAMICS	
4.1 OVERVIEW	25
4.2 DRIVERS	26
4.2.1 INCREASING DEMAND FOR DRY POWDER INHALER (DPI) PRODUCTS	26
4.2.2 COMPATIBILITY WITH ACTIVE PHARMACEUTICAL INGREDIENTS AND OTHER EXCIPIENTS	26
4.2.3 RISING RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY	26
4.3 RESTRAINTS	27

4.3.1 LACTOSE INDUCED PROBLEMS	27
4.3.2 STRINGENT GOVERNMENT REGULATIONS	27
4.3.3 LACK OF COMPATIBILITY WITH AMINE-BASED DRUGS	28
4.4 OPPORTUNITIES	28
4.4.1 DRUG FORMULATION WITH NANOTECHNOLOGY WILL BOOST THE GROWTH OF THE PHARMACEUTICAL GRADE LACTOSE MARKET	28
5 MARKET FACTOR ANALYSIS	
5.1 PORTER'S FIVE FORCES MODEL	29
5.1.1 THREAT OF NEW ENTRANTS	30
5.1.2 BARGAINING POWER OF SUPPLIERS	30
5.1.3 THREAT OF SUBSTITUTES	30
5.1.4 BARGAINING POWER OF BUYERS	30
5.1.5 INTENSITY OF RIVALRY	30
5.2 VALUE CHAIN ANALYSIS	31
5.2.1 R&D	32
5.2.2 MANUFACTURING	32
5.2.3 DISTRIBUTION & SALES	32
5.2.4 POST-SALES MONITORING	32
5.3 IMPACT OF COVID-19 ON PHARMACEUTICAL GRADE LACTOSE MARKET	33
5.3.1 OVERVIEW	33
5.3.2 IMPACT ON SUPPLY CHAIN	33
5.3.3 IMPACT ON PRODUCTION	34
6 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY TYPE	
6.1 OVERVIEW	35
6.2 CRYSTALLINE MONOHYDRATE LACTOSE	36
6.3 INHALATION LACTOSE	37
6.4 GRANULATED LACTOSE	38
6.5 SPRAY DRIED LACTOSE	39
7 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY APPLICATION	
7.1 INTRODUCTION	41
7.2 TABLETS MANUFACTURING	42
7.3 CAPSULE MANUFACTURING	43
8 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY REGION	
8.1 INTRODUCTION	45
8.2 EUROPE	46
8.2.1 WESTERN EUROPE	49
8.2.1.1 GERMANY	53
8.2.1.2 FRANCE	56
8.2.1.3 UK	58
8.2.1.4 ITALY	61
8.2.1.5 SPAIN	64
8.2.1.6 REST OF WESTERN EUROPE	67
8.2.2 EASTERN EUROPE	70
8.3 ASIA-PACIFIC	73
8.3.1 CHINA	77
8.3.2 JAPAN	79
8.3.3 INDIA	82

8.3.4 SOUTH KOREA	85
8.3.5 AUSTRALIA	88
8.3.6 REST OF ASIA-PACIFIC	91
8.4 AMERICAS	94
8.4.1 NORTH AMERICA	97
8.4.1.1 US	101
8.4.1.2 CANADA	104
8.4.2 SOUTH AMERICA	107
8.5 MIDDLE EAST & AFRICA	110
8.5.1 MIDDLE EAST	113
8.5.2 AFRICA	116
9 COMPETITIVE LANDSCAPE	
9.1 OVERVIEW	119
9.2 COMPETITIVE BENCHMARKING	120
9.3 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET: COMPANY RANK ANALYSIS	120
9.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS	121
9.5 MAJOR GROWTH STRATEGY IN THE GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET	121
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES	121
9.6.1 PRODUCT APPROVALS	121
9.6.2 ACQUISITIONS	122
9.6.3 EXPANSIONS	122
9.7 FINANCIAL MATRIX	122
10 COMPANY PROFILES	
10.1 KERRY INC.	124
10.1.1 COMPANY OVERVIEW	124
10.1.2 FINANCIAL OVERVIEW	124
10.1.3 PRODUCTS/SERVICES OFFERED	125
10.1.4 KEY DEVELOPMENTS	125
10.1.5 SWOT ANALYSIS	126
10.1.6 KEY STRATEGIES	126
10.2 DFE PHARMA	127
10.2.1 COMPANY OVERVIEW	127
10.2.2 FINANCIAL OVERVIEW	127
10.2.3 PRODUCTS/SERVICES OFFERED	127
10.2.4 KEY DEVELOPMENTS	128
10.2.5 SWOT ANALYSIS	128
10.2.6 KEY STRATEGIES	129
10.3 MEGGLE EXCIPIENTS & TECHNOLOGY	130
10.3.1 COMPANY OVERVIEW	130
10.3.2 FINANCIAL OVERVIEW	130
10.3.3 PRODUCTS OFFERED	130
10.3.4 KEY DEVELOPMENTS	130
10.3.5 SWOT ANALYSIS	131
10.3.6 KEY STRATEGIES	131
10.4 MERCK KGAA	132
10.4.1 COMPANY OVERVIEW	132

10.4.2 FINANCIAL OVERVIEW	132
10.4.3 PRODUCTS/SERVICES OFFERED	133
10.4.4 KEY DEVELOPMENTS	133
10.4.5 SWOT ANALYSIS	134
10.4.6 KEY STRATEGIES	134
10.5 ARMOR PHARMA	135
10.5.1 COMPANY OVERVIEW	135
10.5.2 FINANCIAL OVERVIEW	135
10.5.3 PRODUCTS/SERVICES OFFERED	135
10.5.4 KEY DEVELOPMENTS	135
10.5.5 SWOT ANALYSIS	136
10.5.6 KEY STRATEGIES	136
10.6 ALPAVIT	137
10.6.1 COMPANY OVERVIEW	137
10.6.2 FINANCIAL OVERVIEW	137
10.6.3 PRODUCTS/SERVICES OFFERED	137
10.6.4 KEY DEVELOPMENTS	137
10.6.5 SWOT ANALYSIS	138
10.6.6 KEY STRATEGIES	138
10.7 BASF SE	139
10.7.1 COMPANY OVERVIEW	139
10.7.2 FINANCIAL OVERVIEW	139
10.7.3 PRODUCTS OFFERED	140
10.7.4 KEY DEVELOPMENTS	140
10.7.5 SWOT ANALYSIS	140
10.7.6 KEY STRATEGIES	140
11 APPENDIX	
11.1 REFERENCES	141
11.2 RELATED REPORTS	141
12 LIST OF TABLES	
TABLE 1 LIST OF ASSUMPTIONS	17
TABLE 2 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	36
TABLE 3 GLOBAL CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY REGION, 2020–2027 (USD MILLION)	36
TABLE 4 GLOBAL CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	37
TABLE 5 GLOBAL A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION)	37
TABLE 6 GLOBAL INHALATION LACTOSE MARKET, BY REGION, 2020–2027 (USD MILLION)	38
TABLE 7 GLOBAL INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	38
TABLE 8 GLOBAL GRANULATED LACTOSE MARKET, BY REGION, 2020–2027 (USD MILLION)	39
TABLE 9 GLOBAL SPRAY DRIED LACTOSE MARKET, BY REGION, 2020–2027 (USD MILLION)	40
TABLE 10 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)	42
TABLE 11 GLOBAL PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY REGION 2020–2027 (USD MILLION)	42
TABLE 12 GLOBAL PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	43
TABLE 13 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY REGION 2020–2027 (USD MILLION)	43
TABLE 14 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	44



TABLE 15 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY REGION, 2020–2027 (USD MILLION)	45
TABLE 16 EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY REGION, 2020–2027 (USD MILLION)	46
TABLE 17 EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION)	47
TABLE 18 EUROPE CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	47
TABLE 19 EUROPE A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION)	47
TABLE 20 EUROPE INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	48
TABLE 21 EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION)	48
TABLE 22 EUROPE PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	48
TABLE 23 EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	49
TABLE 24 WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY COUNTRY, 2020–2027 (USD MILLION)	50
TABLE 25 WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION)	50
TABLE 26 WESTERN EUROPE CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	51
TABLE 27 WESTERN EUROPE A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION)	51
TABLE 28 WESTERN EUROPE INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	51
TABLE 29 WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION)	52
TABLE 30 WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	52
TABLE 31 WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	52
TABLE 32 GERMANY PHARMACEUTICAL GRADE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	53
TABLE 33 GERMANY CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	53
TABLE 34 GERMANY A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION)	54
TABLE 35 GERMANY INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	54
TABLE 36 GERMANY PHARMACEUTICAL GRADE LACTOSE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)	54
TABLE 37 GERMANY PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	55
TABLE 38 GERMANY PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	55
TABLE 39 FRANCE PHARMACEUTICAL GRADE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	56
TABLE 40 FRANCE CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	56
TABLE 41 FRANCE A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION)	56
TABLE 42 FRANCE INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	57
TABLE 43 FRANCE PHARMACEUTICAL GRADE LACTOSE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)	57
TABLE 44 FRANCE PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	57
TABLE 45 FRANCE PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION)	58
TABLE 46 UK PHARMACEUTICAL GRADE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	58
TABLE 47 UK CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	59
TABLE 48 UK A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION)	59
TABLE 49 UK INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION)	59
TABLE 50 UK PHARMACEUTICAL GRADE LACTOSE MARKET, BY APPLICATION, 2020–2027 (USD MILLION)	60
TABLE 51 UK PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION	

TYPE, 2020–2027 (USD MILLION) 60

TABLE 52 UK PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 60

TABLE 53 ITALY PHARMACEUTICAL GRADE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 54 ITALY CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

TABLE 55 ITALY A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 56 ITALY INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 57 ITALY PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 62

TABLE 58 ITALY PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 63

TABLE 59 ITALY PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 63

TABLE 60 SPAIN PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 61 SPAIN CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 62 SPAIN A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 63 SPAIN INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 64 SPAIN PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 65

TABLE 65 SPAIN PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 66

TABLE 66 SPAIN PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 66

TABLE 67 REST OF WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 68 REST OF WESTERN EUROPE CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 69 REST OF WESTERN EUROPE A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 70 REST OF WESTERN EUROPE INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 71 REST OF WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 68

TABLE 72 REST OF WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 69

TABLE 73 REST OF WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 69

TABLE 74 EASTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 75 EASTERN EUROPE CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 76 EASTERN EUROPE A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 77 EASTERN EUROPE INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 78 EASTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 71

TABLE 79 EASTERN EUROPE PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 72

TABLE 80 EASTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 72

TABLE 81 ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73

TABLE 82 ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 83 ASIA-PACIFIC CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 84 ASIA-PACIFIC A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 85 ASIA-PACIFIC INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 86 ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD

MILLION) 75

TABLE 87 ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 76

TABLE 88 ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 76

TABLE 89 CHINA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 90 CHINA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 91 CHINA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 92 CHINA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 93 CHINA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 78

TABLE 94 CHINA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 78

TABLE 95 CHINA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 79

TABLE 96 JAPAN PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 97 JAPAN CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 98 JAPAN A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 99 JAPAN INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 100 JAPAN PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 81

TABLE 101 JAPAN PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 81

TABLE 102 JAPAN PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 81

TABLE 103 INDIA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 104 INDIA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 105 INDIA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 106 INDIA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 107 INDIA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 83

TABLE 108 INDIA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 84

TABLE 109 INDIA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 84

TABLE 110 SOUTH KOREA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 111 SOUTH KOREA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 112 SOUTH KOREA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 113 SOUTH KOREA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 114 SOUTH KOREA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 86

TABLE 115 SOUTH KOREA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 87

TABLE 116 SOUTH KOREA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 87

TABLE 117 AUSTRALIA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 118 AUSTRALIA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 119 AUSTRALIA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 120 AUSTRALIA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 121 AUSTRALIA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 89

TABLE 122 AUSTRALIA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 90

TABLE 123 AUSTRALIA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 90

TABLE 124 REST OF ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 125 REST OF ASIA-PACIFIC CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 126 REST OF ASIA-PACIFIC A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 127 REST OF ASIA-PACIFIC INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 128 REST OF ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 92

TABLE 129 REST OF ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 93

TABLE 130 REST OF ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 93

TABLE 131 AMERICAS PHARMACEUTICAL GRADE LACTOSE MARKET, BY REGION, 2020–2027 (USD MILLION) 94

TABLE 132 AMERICAS PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 133 AMERICAS CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 134 AMERICAS A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 135 AMERICAS INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 136 AMERICAS PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 96

TABLE 137 AMERICAS PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 96

TABLE 138 AMERICAS PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 97

TABLE 139 NORTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 98

TABLE 140 NORTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 141 NORTH AMERICA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 142 NORTH AMERICA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 143 NORTH AMERICA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 144 NORTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 99

TABLE 145 NORTH AMERICA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 100

TABLE 146 NORTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 100

TABLE 147 US PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 148 US CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 149 US A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 150 US INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 151 US PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 102

TABLE 152 US PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 103

TABLE 153 US PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 103

TABLE 154 CANADA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 155 CANADA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 156 CANADA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 157 CANADA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 105

TABLE 158 CANADA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 105

TABLE 159 CANADA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 106

TABLE 160 CANADA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 106

TABLE 161 SOUTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 162 SOUTH AMERICA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 163 SOUTH AMERICA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 164 SOUTH AMERICA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 165 SOUTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 108

TABLE 166 SOUTH AMERICA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 108

TABLE 167 SOUTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 109

TABLE 168 MIDDLE EAST & AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET BY REGION, 2020–2027 (USD MILLION) 110

TABLE 169 MIDDLE EAST & AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 170 MIDDLE EAST & AFRICA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 171 MIDDLE EAST & AFRICA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 111

TABLE 172 MIDDLE EAST & AFRICA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 173 MIDDLE EAST & AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 112

TABLE 174 MIDDLE EAST & AFRICA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 112

TABLE 175 MIDDLE EAST & AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 113

TABLE 176 MIDDLE EAST PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 177 MIDDLE EAST CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 114

TABLE 178 MIDDLE EAST A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 114

TABLE 179 MIDDLE EAST INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 114

TABLE 180 MIDDLE EAST PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 (USD MILLION) 115

TABLE 181 MIDDLE EAST PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 115

TABLE 182 MIDDLE EAST PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 115

TABLE 183 AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020–2027 (USD MILLION) 116

TABLE 184 AFRICA CRYSTALLINE MONOHYDRATE LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 116

TABLE 185 AFRICA A-LACTOSE MONOHYDRATE MARKET, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 186 AFRICA INHALATION LACTOSE MARKET, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 187 AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET BY APPLICATION, 2020–2027 117

TABLE 188 AFRICA PHARMACEUTICAL GRADE LACTOSE, FOR TABLETS MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 118

TABLE 189 AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET, FOR CAPSULE MANUFACTURING, BY APPLICATION TYPE, 2020–2027 (USD MILLION) 118

TABLE 190 MAJOR MANUFACTURERS COMPANY RANK ANALYSIS, 2020 120

TABLE 191 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE PHARMACEUTICAL GRADE LACTOSE MARKET 121

TABLE 192 PRODUCT APPROVALS	121
TABLE 193 ACQUISITIONS	122
TABLE 194 EXPANSIONS	122
TABLE 195 KERRY INC.: PRODUCTS/SERVICES OFFERED	125
TABLE 196 KERRY INC.: KEY DEVELOPMENTS	125
TABLE 197 DFE PHARMA: PRODUCTS/SERVICES OFFERED	127
TABLE 198 DFE PHARMA: KEY DEVELOPMENTS	128
TABLE 199 MEGGLE EXCIPIENTS & TECHNOLOGY: PRODUCTS/SERVICES OFFERED	130
TABLE 200 MEGGLE EXCIPIENTS & TECHNOLOGY: KEY DEVELOPMENTS	130
TABLE 201 MERCK KGAA: PRODUCTS/SERVICES OFFERED	133
TABLE 202 MERCK KGAA: KEY DEVELOPMENTS	133
TABLE 203 ARMOR PHARMA: PRODUCTS/SERVICES OFFERED	135
TABLE 204 ALPAVIT: PRODUCTS/SERVICES OFFERED	137
TABLE 205 BASF SE: PRODUCTS OFFERED	140
13 LIST OF FIGURES	
FIGURE 1 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET STRUCTURE	18
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES	23
FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET	25
FIGURE 4 DRIVERS IMPACT ANALYSIS	27
FIGURE 5 RESTRAINTS IMPACT ANALYSIS	28
FIGURE 6 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET	29
FIGURE 7 VALUE CHAIN ANALYSIS OF THE GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET	31
FIGURE 8 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET BY TYPE, 2020 AND 2027 (USD MILLION)	35
FIGURE 9 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET, BY APPLICATION, 2020 AND 2027 (USD MILLION)	41
FIGURE 10 GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET SHARE, BY REGION, 2020 (%)	45
FIGURE 11 EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET SHARE, BY REGION, 2020 (%)	46
FIGURE 12 WESTERN EUROPE PHARMACEUTICAL GRADE LACTOSE MARKET SHARE, BY COUNTRY, 2020 (%)	49
FIGURE 13 ASIA-PACIFIC PHARMACEUTICAL GRADE LACTOSE MARKET SHARE, BY COUNTRY, 2020 (%)	73
FIGURE 14 AMERICAS PHARMACEUTICAL GRADE LACTOSE MARKET SHARE, BY REGION, 2020 (%)	94
FIGURE 15 NORTH AMERICA PHARMACEUTICAL GRADE LACTOSE MARKET SHARE, BY COUNTRY, 2020 (%)	97
FIGURE 16 MIDDLE EAST & AFRICA PHARMACEUTICAL GRADE LACTOSE MARKET, BY REGION, 2020 (%)	110
FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS	120
FIGURE 18 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL PHARMACEUTICAL GRADE LACTOSE MARKET	121
FIGURE 19 SALES & OPERATING INCOME MARGIN, 2020	122
FIGURE 20 RESEARCH & DEVELOPMENT EXPENDITURE, 2020	123
FIGURE 21 KERRY INC.: FINANCIAL OVERVIEW SNAPSHOT	124
FIGURE 22 KERRY INC.: SWOT ANALYSIS	126
FIGURE 23 DFE PHARMA: SWOT ANALYSIS	128
FIGURE 24 MEGGLE EXCIPIENTS & TECHNOLOGY: SWOT ANALYSIS	131
FIGURE 25 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT	132
FIGURE 26 MERCK KGAA: SWOT ANALYSIS	134
FIGURE 27 ARMOR PHARMA: SWOT ANALYSIS	136
FIGURE 28 ALPAVIT: SWOT ANALYSIS	138

FIGURE 29 BASF SE: FINANCIAL OVERVIEW SNAPSHOT 139

FIGURE 30 BASF SE: SWOT ANALYSIS 140

---

<https://www.marketresearchfuture.com> / Phone +1 628 258 0071(US) / +44 2035 002 764(UK)